The Role of Organoid‐Based Drug Sensitivity Testing in Clinical Cancer Therapy
Organ Medicine · 2024
DOI: 10.1002/orm2.12 ↗At a glance
Journal article in Organ Medicine, 2024. Written by Huan Yang and 5 co-authors. 10 references. The full text is freely available (open access, CC BY 4.0).
Abstract (original language)
In recent years, cancer has become a significant global health burden, with rising incidence rates emphasizing the need for innovative therapeutic strategies. Among these, organoid models have emerged as transformative platforms, offering unprecedented insights into tumor biology, drug screening, and therapeutic responses. This editorial explores the evolving role of organoids in precision oncology, highlighting their potential to bridge the gap between preclinical research and personalized medicine.
Cite
APA
Yang, H., Liu, Y., Li, J., He, Y., Zeng, L., & Pan, Y. (2024). The Role of Organoid‐Based Drug Sensitivity Testing in Clinical Cancer Therapy. Organ Medicine. https://doi.org/10.1002/orm2.12
Vancouver
Yang H, Liu Y, Li J, He Y, Zeng L, Pan Y. The Role of Organoid‐Based Drug Sensitivity Testing in Clinical Cancer Therapy. Organ Medicine. 2024. doi:10.1002/orm2.12
BibTeX
@article{Yang2024,
author = {Yang, Huan and Liu, Yuhong and Li, Jia and He, Yulong and Zeng, Leli and Pan, Yihang},
title = {The Role of Organoid‐Based Drug Sensitivity Testing in Clinical Cancer Therapy},
journal = {Organ Medicine},
year = {2024},
doi = {10.1002/orm2.12}
}
EUVIMED